IL33 and Insulin resistance: In addition, IL-33-treated mice showed a significant decrease in the severity of HFD-induced insulin resistance and glucose intolerance (Figure 2f and 2g), which were indicated by changes in plasma levels of glucose in response to a peritoneal injection of insulin and glucose, respectively.